Asian Pacific Journal of Cancer Prevention

  • 제17권9호
  • /
  • Pages.4415-4420
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지

Hepatitis C Virus Associations with Non Hodgkin's Lymphoma: Insights on Inflammation/Angiogenesis and CD Markers

  • El-Maadawy, Eman A (Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City) ;
  • Talaat, Roba M (Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City) ;
  • Sadek, Rawia F (Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City) ;
  • El-Sherbini, Sherif M (Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City) ;
  • Abdel-Bary, Naser (Clinical Oncology Department, Faculty of Medicine, Menufia University) ;
  • Abdel-Aziz, Amal A (Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City)
  • 발행 : 2016.09.01
⟨ 이전 논문 다음 논문 ⟩

초록

We aimed to investigate any association between hepatitis C virus (HCV) infection and non-Hodgkin's lymphoma (NHL) in the view of cytokines that control inflammation/angiogenesis and their correlation with certain CD markers. NHL patients with or without HCV infection were studied. CD5, CD30, CD3, CD20 and CD45 were immunohistochemically evaluated. Plasma levels of vascular endothelial and platelet derived growth factors (VEGF, and PDGF), tumor necrosis factor (TNF-${\alpha}$), transforming growth factor (TGF-${\beta}$), interleukin-6 (IL-6), IL-8, IL-4, IL-12 and interferon gamma (IFN-${\gamma}$) were detected by enzyme-linked immunosorbent assay (ELISA). HCV+ve NHL patients showed a significant reduction in VEGF, PDGF, IFN-${\gamma}$, CD5 and CD45 and a significant increase in IL-12 and IL-8. In conclusion, there was a significant change in cytokine secretion and expression of CD markers in HCV+ve NHL patients. Based on our results, HCV infection in NHL patients requires more in-depth investigations to explore any role in lymphoma progression.

키워드

참고문헌

  1. Anderson, LA, Engels EA (2008). Hepatitis C virus infection and non-Hodgkin lymphoma: interesting association or causal relationship? Int J Cancer, 122, 10-12.
  2. Anderson LA, Pfeiffer R, Warren JL, et al (2008). Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev, 17, 3069-75. https://doi.org/10.1158/1055-9965.EPI-08-0408
  3. Arcaini L, Merli M, Volpetti S, et al (2012). Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol, 638, 185.
  4. Cowgill KD, Loffredo CA, Eissa SA, et al (2004). Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol, 33, 1034-9. https://doi.org/10.1093/ije/dyh183
  5. Curado MP, Edwards B, Shin HR, et al (2007). Cancer Incidence in Five Continents. Vol. 9. Lyon, France: IARC; 961p.
  6. De Re V, Caggiari L, Garziera M, De Zorzi M, Repetto O (2012). Molecular signature in HCV-positive lymphomas. Clin Dev Immunol, 2012, 623465.
  7. Dolganiuc A, Oak S, Kodys K, et al (2004). Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterol, 127, 1513-24. https://doi.org/10.1053/j.gastro.2004.08.067
  8. Duberg AS, Nordstrom M, Torner A, et al (2005). Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatol, 41, 652-9. https://doi.org/10.1002/hep.20608
  9. Fallahi P, Ferri C, Ferrari SM, et al (2012). Cytokines and HCVrelated disorders. Clin Dev Immunol, 468107.
  10. Farawela H, Khorshied M, Shaheen I (2012). The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin's lymphoma risk in Egypt. Infect Genet Evol, 12, 1189-94. https://doi.org/10.1016/j.meegid.2012.04.007
  11. Feldmann G, Nischalke HD, Nattermann J, et al (2006) Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res, 12, 4491-8. https://doi.org/10.1158/1078-0432.CCR-06-0154
  12. Ferri C, Caracciolo F, Zignego AL, et al (1994). Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol, 88, 392-4. https://doi.org/10.1111/j.1365-2141.1994.tb05036.x
  13. Freedman LS (2006). National cancer institute, middle east cancer consortium. cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the middle east cancer consortium (MECC) compared with US SEER. NIH Pub. No. 06-5873. Bethesda, MD: 150.5.
  14. Gervasi F, Lo Verso R, Giambanco C, et al (2004). Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites. Ann N Y Acad Sci, 1028, 457-62. https://doi.org/10.1196/annals.1322.054
  15. Goldman L, Ezzat S, Mokhtar N, et al (2009). Viral and nonviral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control, 20, 981-7. https://doi.org/10.1007/s10552-009-9316-0
  16. Gu Y, Shore RE, Arslan AA (2010). Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control, 21, 1323-33. https://doi.org/10.1007/s10552-010-9560-3
  17. Hamdy HS, Abdelkader NA, Mansour A, et al (2015). B cell non-Hodgkin's lymphoma in chronic hepatitis C virus patients: An interesting relationship. Indian J Gastroenterol, 34, 127-34. https://doi.org/10.1007/s12664-015-0549-4
  18. Harakati MS, Abualkhair OA, Al-Knawy BA (2000). Hepatitis C Virus infection in Saudi Arab patients with B-cell non-Hodgkin's lymphoma. Saudi Med J, 21, 755-8.
  19. Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS (2012). Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatol, 55, 634-41. https://doi.org/10.1002/hep.25499
  20. Izumi T, Sasaki R, Tsunoda S, et al (1997). B cell malignancy and hepatitis C virus infection. Leukemia, 11, 516-8.
  21. Kasamon YL, Swinnen LJ (2004). Treatment advances in adult Burkitt's lymphoma and leukemia. Curr Opin Oncol, 16, 429-35. https://doi.org/10.1097/00001622-200409000-00003
  22. Lech-Maranda E, Baseggio L, Bienvenu J, et al (2004). Interleukin-10 gene promoter polymorphisms influence the clinical outcome of Diffuse large B-cell lymphoma. Blood, 103, 3529-34. https://doi.org/10.1182/blood-2003-06-1850
  23. Libra M, Mangano K, Anzaldi M, et al (2006). Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCVassociated lymphoproliferative disorders. Oncol Rep, 15, 1305-8.
  24. Marcucci F, Mele A (2011). Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood, 117, 1792-8. https://doi.org/10.1182/blood-2010-06-275818
  25. Marignani M, Mangone M, Cox MC, et al (2011). HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Dig Liver Dis, 43, 139-42. https://doi.org/10.1016/j.dld.2010.05.010
  26. Mazzaro C, Zagonel V, Monfardini S, et al (1996). Hepatitis C virus and non-Hodgkin's lymphomas. Br J Haematol, 94, 544-50. https://doi.org/10.1046/j.1365-2141.1996.6912313.x
  27. Mele A, Pulsoni A, Bianco E, et al (2003). Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood, 102, 996-9. https://doi.org/10.1182/blood-2002-10-3230
  28. Miller FD, Abu-Raddad LJ (2010). Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A, 107, 14757-62. https://doi.org/10.1073/pnas.1008877107
  29. Mizorogi F, Hiramoto J, Nozato A, et al (2000). Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma. Intern Med, 39, 112-7. https://doi.org/10.2169/internalmedicine.39.112
  30. Murakami J, and Watanabe M (1997). Hepatitis C virus and malignant lymphomas. Jpn J Gastroenterol, 94, 174.
  31. Napoli J, Bishop GA, McCaughan GW (1994). Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Gastroenterol, 107, 789-98. https://doi.org/10.1016/0016-5085(94)90128-7
  32. Palmeira C, Sousa ME, Godinho I, et al (2012). Flow cytometry CD45-negative B-NHL: a case report of a diffuse large B-cell lymphoma without extranodal involvement. Cytometry B Clin Cytom, 82, 369-71.
  33. Pawelczyk A, Kubisa N, Jablonska J, et al (2013). Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+.Virol J, 10, 346. https://doi.org/10.1186/1743-422X-10-346
  34. Pei JH, Luo SQ, Chen JH, Xiao HW, Hu WX (2011). The association between non-Hodgkin lymphoma and methylation of p73. Tumour Biol, 32, 1133-8. https://doi.org/10.1007/s13277-011-0215-0
  35. Rastin M, Khoee AR, Tabasi N, et al (2013). Evaluation of HTLV-I and HCV Prevalence in Non-Hodgkin's Lymphoma. Iran J Basic Med Sci, 16, 242-6.
  36. Silvestri F, Pipan C, Barillari G, et al (1996). Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood, 87, 4296-301.
  37. Steinke JW and Borish L (2006). Cytokines and chemokines. J Allergy Clin Immunol, 11, 441-5.
  38. Sung VM, Shimodaira S, Doughty AL, et al (2003). Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol, 77, 2134-46. https://doi.org/10.1128/JVI.77.3.2134-2146.2003
  39. Talaat RM (2010). Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Viral Immunol, 23, 151-7. https://doi.org/10.1089/vim.2009.0089
  40. Talaat RM, Abdel-Aziz AM, El-Maadawy EA, Abdel-Bary N (2014). Interleukin 10 gene promoter polymorphism and risk of diffuse large B cell lymphoma (DLBCL). Egypt J Med Hum Gen, 15, 7-13. https://doi.org/10.1016/j.ejmhg.2013.09.001
  41. Talaat RM, El-Bassiouny AI, Osman AM, et al (2007). Cytokine secretion profile associated with periportal fibrosis in S. mansoni-infected egyptian patients. Parasitol Res, 101, 289-99. https://doi.org/10.1007/s00436-007-0478-y
  42. Talaat RM, Salem TA, El-Masry S, et al (2014). Circulating pro- and anti-angiogenic mediators in patients infected with hepatitis C at different stages of hepatocellular carcinoma. J Med Virol, 86, 1120-9. https://doi.org/10.1002/jmv.23932
  43. Talaulikar D, Dahlstrom JE, Shadbolt B, Broomfield A, McDonald A (2008) Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL). J Histochem Cytochem, 56, 893-900. https://doi.org/10.1369/jhc.2008.951087
  44. Vendrame E, Martinez-Maza O (2011). Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. J Proteome Res, 10, 113-9. https://doi.org/10.1021/pr100729z
  45. Yoshikawa M, Imazu H, Ueda S, et al (1997). Prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma and multiple myeloma. A report from Japan. J Clin Gastroenterol, 25, 713-4. https://doi.org/10.1097/00004836-199712000-00044
  46. Zuckerman E, Zuckerman T, Levine AM, et al (1997). Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med, 127, 423-8. https://doi.org/10.7326/0003-4819-127-6-199709150-00002